» Authors » Achim Jungbluth

Achim Jungbluth

Explore the profile of Achim Jungbluth including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 43
Citations 2200
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou T, Sardana R, Eren O, Pulitzer M, Jungbluth A, Dogan A, et al.
Mod Pathol . 2025 Jan; 38(6):100725. PMID: 39884434
T-cell clonality assessment constitutes an essential part of the diagnostic evaluation of suspected T-cell neoplasms. Recent advances in flow cytometry-based analysis of TCR β-chain constant region 1 (TRBC1) have introduced...
2.
Ng S, Stephan C, Do M, Frosina D, Jungbluth A, Busam K, et al.
J Cutan Pathol . 2024 Dec; 52(3):244-249. PMID: 39698761
Background: Mpox (formerly known as monkeypox), a zoonotic disease caused by Monkeypox virus (MPXV), has become an international outbreak since May 2022. Mpox often presents with a mild systemic illness...
3.
Xu B, Jungbluth A, Frosina D, Alabkaa A, Serrette R, Qin H, et al.
Head Neck Pathol . 2024 Nov; 18(1):123. PMID: 39589616
Purpose: BSND is a chloride channel subunit that is expressed in the normal salivary gland. We aimed to validate the utility of BSND immunohistochemistry in the differential diagnosis of oncocytic...
4.
Xu B, Baine M, Jungbluth A, Alabkaa A, Serrette R, Roy D, et al.
J Clin Endocrinol Metab . 2024 Sep; PMID: 39324657
Purpose: Seizure-related 6 homolog (SEZ6) is a cDNA that strongly associated with neuroendocrine differentiation. Recently, SEZ6 expression was found in a subset of small cell lung carcinoma (SCLC). Furthermore, ABBV-011,...
5.
Vaughn B, Lee S, Vargas D, Seo S, Rinne S, Xu H, et al.
J Nucl Med . 2024 Aug; 65(10):1611-1618. PMID: 39168519
Radiolabeled small-molecule DOTA-haptens can be combined with antitumor/anti-DOTA bispecific antibodies (BsAbs) for pretargeted radioimmunotherapy (PRIT). For optimized delivery of the theranostic γ- and β-emitting isotope Lu with DOTA-based PRIT (DOTA-PRIT),...
6.
Torrence D, Dermawan J, Zhang Y, Vanderbilt C, Hwang S, Mullaney K, et al.
Histopathology . 2024 Jun; 85(6):889-898. PMID: 38890779
Aims: Chondromyxoid fibroma (CMF) is a rare, benign bone tumour which arises primarily in young adults and is occasionally diagnostically challenging. Glutamate metabotropic receptor 1 (GRM1) gene encodes a metabotropic...
7.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv . 2024 Apr; PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
8.
Liu Y, Sardana R, Nemirovsky D, Frosina D, Jungbluth A, Johnson W, et al.
Blood Adv . 2024 Apr; 8(12):3064-3075. PMID: 38593227
Although significant progress has been made in understanding the genetic basis of primary hemophagocytic lymphohistiocytosis (HLH), the pathogenesis of secondary HLH, the more prevalent form, remains unclear. Among the various...
9.
Alghamdi M, Chen J, Jungbluth A, Koutzaki S, Palmer M, Al-Ahmadie H, et al.
Mod Pathol . 2024 Mar; 37(5):100467. PMID: 38460672
Renal low-grade oncocytic tumor (LOT) is a recently recognized renal cell neoplasm designated within the "other oncocytic tumors" category in the 2022 World Health Organization classification system. Although the clinicopathologic,...
10.
Sato H, Kubota D, Qiao H, Jungbluth A, Rekhtman N, Schoenfeld A, et al.
JCO Precis Oncol . 2022 Aug; 6:e2200088. PMID: 35952318
Purpose: The identification of novel oncogenic driver alterations and novel mechanisms of acquired resistance (AR) is the key for further development of personalized therapy. The current study investigates the potential...